Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Disruption of IRE1α through its kinase domain attenuates multiple myeloma.

Harnoss JM, Le Thomas A, Shemorry A, Marsters SA, Lawrence DA, Lu M, Chen YA, Qing J, Totpal K, Kan D, Segal E, Merchant M, Reichelt M, Ackerly Wallweber H, Wang W, Clark K, Kaufman S, Beresini MH, Laing ST, Sandoval W, Lorenzo M, Wu J, Ly J, De Bruyn T, Heidersbach A, Haley B, Gogineni A, Weimer RM, Lee D, Braun MG, Rudolph J, VanWyngarden MJ, Sherbenou DW, Gomez-Bougie P, Amiot M, Acosta-Alvear D, Walter P, Ashkenazi A.

Proc Natl Acad Sci U S A. 2019 Aug 13;116(33):16420-16429. doi: 10.1073/pnas.1906999116. Epub 2019 Aug 1.

2.

BCL2-Family Dysregulation in B-Cell Malignancies: From Gene Expression Regulation to a Targeted Therapy Biomarker.

Tessoulin B, Papin A, Gomez-Bougie P, Bellanger C, Amiot M, Pellat-Deceunynck C, Chiron D.

Front Oncol. 2019 Jan 7;8:645. doi: 10.3389/fonc.2018.00645. eCollection 2018.

3.

Interactions between cancer-associated fibroblasts and tumor cells promote MCL-1 dependency in estrogen receptor-positive breast cancers.

Louault K, Bonneaud TL, Séveno C, Gomez-Bougie P, Nguyen F, Gautier F, Bourgeois N, Loussouarn D, Kerdraon O, Barillé-Nion S, Jézéquel P, Campone M, Amiot M, Juin PP, Souazé F.

Oncogene. 2019 Apr;38(17):3261-3273. doi: 10.1038/s41388-018-0635-z. Epub 2019 Jan 10.

4.

Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways.

Tessoulin B, Moreau-Aubry A, Descamps G, Gomez-Bougie P, Maïga S, Gaignard A, Chiron D, Ménoret E, Le Gouill S, Moreau P, Amiot M, Pellat-Deceunynck C.

J Hematol Oncol. 2018 Dec 13;11(1):137. doi: 10.1186/s13045-018-0679-0.

5.

BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment.

Gomez-Bougie P, Maiga S, Tessoulin B, Bourcier J, Bonnet A, Rodriguez MS, Le Gouill S, Touzeau C, Moreau P, Pellat-Deceunynck C, Amiot M.

Blood. 2018 Dec 20;132(25):2656-2669. doi: 10.1182/blood-2018-03-836718. Epub 2018 Oct 11.

6.

Repression of Mcl-1 and disruption of the Mcl-1/Bak interaction in myeloma cells couple ER stress to mitochondrial apoptosis.

Gomez-Bougie P, Halliez M, Moreau P, Pellat-Deceunynck C, Amiot M.

Cancer Lett. 2016 Dec 28;383(2):204-211. doi: 10.1016/j.canlet.2016.09.030. Epub 2016 Sep 30.

PMID:
27697610
7.

The selectivity of Marinopyrrole A to induce apoptosis in MCL1high BCL2low expressing myeloma cells is related to its ability to impair protein translation.

Gomez-Bougie P, Dousset C, Descamps G, Schnitzler A, Audiger L, Tessier A, Dubreuil D, Lebreton J, Pellat-Deceunynck C, Amiot M.

Br J Haematol. 2018 Jan;180(1):157-159. doi: 10.1111/bjh.14293. Epub 2016 Aug 14. No abstract available.

PMID:
27523575
8.

BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma.

Dousset C, Maïga S, Gomez-Bougie P, Le Coq J, Touzeau C, Moreau P, Le Gouill S, Chiron D, Pellat-Deceunynck C, Moreau-Aubry A, Amiot M.

Br J Haematol. 2017 Nov;179(4):684-688. doi: 10.1111/bjh.14251. Epub 2016 Jul 29. No abstract available.

PMID:
27471002
9.

BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice.

Hamouda MA, Jacquel A, Robert G, Puissant A, Richez V, Cassel R, Fenouille N, Roulland S, Gilleron J, Griessinger E, Dubois A, Bailly-Maitre B, Goncalves D, Mallavialle A, Colosetti P, Marchetti S, Amiot M, Gomez-Bougie P, Rochet N, Deckert M, Avet-Loiseau H, Hofman P, Karsenti JM, Jeandel PY, Blin-Wakkach C, Nadel B, Cluzeau T, Anderson KC, Fuzibet JG, Auberger P, Luciano F.

J Exp Med. 2016 Aug 22;213(9):1705-22. doi: 10.1084/jem.20150983. Epub 2016 Jul 25.

10.

Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma.

Kervoëlen C, Ménoret E, Gomez-Bougie P, Bataille R, Godon C, Marionneau-Lambot S, Moreau P, Pellat-Deceunynck C, Amiot M.

Oncotarget. 2015 Sep 29;6(29):26922-34. doi: 10.18632/oncotarget.4616.

11.

A simple flow cytometry-based barcode for routine authentication of multiple myeloma and mantle cell lymphoma cell lines.

Maïga S, Brosseau C, Descamps G, Dousset C, Gomez-Bougie P, Chiron D, Ménoret E, Kervoelen C, Vié H, Cesbron A, Moreau-Aubry A, Amiot M, Pellat-Deceunynck C.

Cytometry A. 2015 Apr;87(4):285-8. doi: 10.1002/cyto.a.22643. Epub 2015 Feb 16. No abstract available.

12.

Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor prognosis subgroups.

Gomez-Bougie P, Halliez M, Maïga S, Godon C, Kervoëlen C, Pellat-Deceunynck C, Moreau P, Amiot M.

Cancer Biol Ther. 2015;16(1):60-5. doi: 10.4161/15384047.2014.986997.

13.

RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway.

Surget S, Descamps G, Brosseau C, Normant V, Maïga S, Gomez-Bougie P, Gouy-Colin N, Godon C, Béné MC, Moreau P, Le Gouill S, Amiot M, Pellat-Deceunynck C.

BMC Cancer. 2014 Jun 14;14:437. doi: 10.1186/1471-2407-14-437.

14.

Apoptotic machinery diversity in multiple myeloma molecular subtypes.

Gomez-Bougie P, Amiot M.

Front Immunol. 2013 Dec 23;4:467. doi: 10.3389/fimmu.2013.00467.

15.

Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells.

Chiron D, Maïga S, Surget S, Descamps G, Gomez-Bougie P, Traore S, Robillard N, Moreau P, Le Gouill S, Bataille R, Amiot M, Pellat-Deceunynck C.

Blood Cancer J. 2013 Jun 7;3:e120. doi: 10.1038/bcj.2013.18.

16.

Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma.

Maïga S, Gomez-Bougie P, Bonnaud S, Gratas C, Moreau P, Le Gouill S, Pellat-Deceunynck C, Amiot M.

Br J Cancer. 2013 May 14;108(9):1801-6. doi: 10.1038/bjc.2013.186. Epub 2013 Apr 30.

17.

Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells.

Surget S, Chiron D, Gomez-Bougie P, Descamps G, Ménoret E, Bataille R, Moreau P, Le Gouill S, Amiot M, Pellat-Deceunynck C.

Cancer Res. 2012 Sep 1;72(17):4562-73. doi: 10.1158/0008-5472.CAN-12-0487. Epub 2012 Jun 27.

18.

The cap-translation inhibitor 4EGI-1 induces apoptosis in multiple myeloma through Noxa induction.

Descamps G, Gomez-Bougie P, Tamburini J, Green A, Bouscary D, Maïga S, Moreau P, Le Gouill S, Pellat-Deceunynck C, Amiot M.

Br J Cancer. 2012 May 8;106(10):1660-7. doi: 10.1038/bjc.2012.139. Epub 2012 Apr 17.

19.

Noxa controls Mule-dependent Mcl-1 ubiquitination through the regulation of the Mcl-1/USP9X interaction.

Gomez-Bougie P, Ménoret E, Juin P, Dousset C, Pellat-Deceunynck C, Amiot M.

Biochem Biophys Res Commun. 2011 Sep 30;413(3):460-4. doi: 10.1016/j.bbrc.2011.08.118. Epub 2011 Sep 1.

PMID:
21907705
20.

ABT-737 is highly effective against molecular subgroups of multiple myeloma.

Bodet L, Gomez-Bougie P, Touzeau C, Dousset C, Descamps G, Maïga S, Avet-Loiseau H, Bataille R, Moreau P, Le Gouill S, Pellat-Deceunynck C, Amiot M.

Blood. 2011 Oct 6;118(14):3901-10. doi: 10.1182/blood-2010-11-317438. Epub 2011 Aug 11.

PMID:
21835956
21.

ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents.

Touzeau C, Dousset C, Bodet L, Gomez-Bougie P, Bonnaud S, Moreau A, Moreau P, Pellat-Deceunynck C, Amiot M, Le Gouill S.

Clin Cancer Res. 2011 Sep 15;17(18):5973-81. doi: 10.1158/1078-0432.CCR-11-0955. Epub 2011 Aug 5.

22.

BH3-only protein Bik is involved in both apoptosis induction and sensitivity to oxidative stress in multiple myeloma.

Bodet L, Ménoret E, Descamps G, Pellat-Deceunynck C, Bataille R, Le Gouill S, Moreau P, Amiot M, Gomez-Bougie P.

Br J Cancer. 2010 Dec 7;103(12):1808-14. doi: 10.1038/sj.bjc.6605981. Epub 2010 Nov 9.

23.

Mcl-1(128-350) fragment induces apoptosis through direct interaction with Bax.

Ménoret E, Gomez-Bougie P, Surget S, Trichet V, Oliver L, Pellat-Deceunynck C, Amiot M.

FEBS Lett. 2010 Feb 5;584(3):487-92. doi: 10.1016/j.febslet.2009.11.094. Epub 2009 Dec 4.

24.

A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45.

Descamps G, Gomez-Bougie P, Venot C, Moreau P, Bataille R, Amiot M.

Br J Cancer. 2009 Jan 27;100(2):366-9. doi: 10.1038/sj.bjc.6604839.

25.

Reciprocal protection of Mcl-1 and Bim from ubiquitin-proteasome degradation.

Wuillème-Toumi S, Trichet V, Gomez-Bougie P, Gratas C, Bataille R, Amiot M.

Biochem Biophys Res Commun. 2007 Oct 5;361(4):865-9. Epub 2007 Jul 24.

PMID:
17681275
26.

Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.

Gomez-Bougie P, Wuillème-Toumi S, Ménoret E, Trichet V, Robillard N, Philippe M, Bataille R, Amiot M.

Cancer Res. 2007 Jun 1;67(11):5418-24.

27.

Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells.

Menoret E, Gomez-Bougie P, Geffroy-Luseau A, Daniels S, Moreau P, Le Gouill S, Harousseau JL, Bataille R, Amiot M, Pellat-Deceunynck C.

Blood. 2006 Aug 15;108(4):1346-52. Epub 2006 Apr 25.

PMID:
16638930
28.

Melphalan-induced apoptosis in multiple myeloma cells is associated with a cleavage of Mcl-1 and Bim and a decrease in the Mcl-1/Bim complex.

Gomez-Bougie P, Oliver L, Le Gouill S, Bataille R, Amiot M.

Oncogene. 2005 Dec 1;24(54):8076-9.

PMID:
16091744
29.
30.

The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells.

Gomez-Bougie P, Bataille R, Amiot M.

Eur J Immunol. 2004 Nov;34(11):3156-64.

Supplemental Content

Loading ...
Support Center